Technology evaluation: TriGem, Titan.

Abstract

Titan (formerly Trilex) is developing TriGem, a monoclonal antibody directed against I17, for the potential treatment of advanced cancers that express the GD2 ganglioside, including melanoma, small-cell lung cancer, neuroblastoma and sarcoma. Phase II trials of TriGem for use in advanced melanoma were ongoing by June 2002. TriGem also has potential for the treatment of psoriasis, for which phase II trials had begun by 1996.

• Authors: Evangelia Razis, George Fountzilas
• Journal: Current opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 5 Issue 2 Pg. 204-7 (Apr 2003) ISSN: 1464-8431 [Print] England
• PMID: 12772513 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Anti-Idiotypic
• Antibodies, Monoclonal
• monoclonal antibody TriGem

Topics

• Animals
• Antibodies, Anti-Idiotypic (administration & dosage, therapeutic use)
• Antibodies, Monoclonal (administration & dosage, biosynthesis, pharmacology, therapeutic use)
• Carcinoma, Small Cell (immunology, therapy)
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Humans
• Immunotherapy
• Macaca fascicularis
• Melanoma (immunology, therapy)
• Mice
• Psoriasis (immunology, therapy)
• Rabbits